The Microbiome Magnified

Emily BurkeBiologics, Biotech Basics, Drug Development, Drug Targets

DECODING THE GUT-BRAIN AXIS There is no shortage of microbiome-focused startups in biotech right now. The link between the gut microbiome — the entire collection of microbes living in the gut — and diseases such as inflammatory bowel disease are well-established. New research has made it clear, however, that the gut microbiome also impacts neurological health, leading to the phrase “the gut-brain … Read More

Decoding The Gut-Brain Axis

Emily BurkeBiologics, Drug Development, Drug Targets, The WEEKLY

Microbiome & Disease The biotech world is abuzz with talk of the latest microbiome startup launch Axial Biotherapeutics (Boston, MA). What caught our eye here at the WEEKLY is the company’s focus on the gut microbiome — the entire collection of microbes living in the gut — and its interplay with the brain. The connection between the gut microbiome and … Read More

On A Tumor’s Turf

Emily BurkeBiologics, Cancer, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Small Molecule Drugs, The WEEKLY

TACKLING THE SPACE AROUND SOLID TUMORS Covering the science behind T-cell-based immunotherapies has been the name of the game for our past couple of issues. CAR-T and TCR therapies show significant promise in early phase blood cancer clinical trials, but what about solid tumors? Previously mentioned Juno Therapeutics’ (Seattle, WA) Armored CAR technology has declared war on tumors, and as you will read … Read More

Unmasking Multiple Sclerosis

Emily BurkeBiologics, Biotech Basics, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs, The WEEKLY

 Many Channels Available To Impede MS Progression Continuing our series on central nervous system (CNS) disorders—previously covering Alzheimer’s and Huntington’s—we pivot to unmask Multiple Sclerosis this week. Famous faces suffering from Multiple Sclerosis (MS) include former talk show host Montel Williams and Sopranos star Jamie-Lynn Sigler. MS typically occurs in susceptible individuals between the ages of 20 and 50, and there are … Read More

Interrupting HIV

Emily BurkeBiologics, Clinical Trials, Drug Development, Drug Targets, Genomics, HIV, Mechanism of Action, Monoclonal Antibodies, Ribonucleic Acid (RNA), Small Molecule Drugs, The WEEKLY

Therapies In HIV Pipeline Medicine has made gigantic strides in understanding and treating the human immunodeficiency virus (HIV) since its emergence in the early 1980s. Thanks to robust drug discovery efforts, today HIV is managed as a chronic disease instead of the death sentence of years past. The secret to HIV’s infectious success lies in its high mutation rate. Developing drug resistance over … Read More

Inching Across The Blood-Brain Barrier

Emily BurkeBiologics, Biotech Basics, Cocktail Fodder, Drug Development, Drug Targets, Monoclonal Antibodies, Term of the Week

A Constant Hurdle in Drug Delivery When it comes to achieving success in drug development, picking the right drug target and developing an effective inhibitor (or activator) is only half the battle. A drug candidate may appear promising in cell-based testing—and even in preclinical testing—but still fail to work in humans. It simply does not get to where it needs to be … Read More

Designer Genes: An Introduction To Genome-Editing

Emily BurkeBiologics, Biotech Basics, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Targets, Genetics, Genomics, HIV, Mechanism of Action, Ribonucleic Acid (RNA), The WEEKLY

Five years ago, altering an individual’s genome would have been labeled unimaginable. Fast forward to today and one of the hottest new developments in biotech is genome-editing—the ability to selectively disable or edit the sequence of specific genes. In this WEEKLY we will compare and contrast the different genome-editing platforms in development and discover how close we are to a clinical reality. Got Gaps in Your … Read More

Sculpting A Better Life For Sickle Cell Patients

Emily BurkeBiologics, Clinical Trials, Cocktail Fodder, Drug Development, Drug Targets, Easily Confused, FDA, Genetics, Mechanism of Action, Monoclonal Antibodies, Orphan Disease, Orphan Drugs, Small Molecule Drugs, The WEEKLY

With the recent announcement of two new biologics in Phase I studies for Sickle Cell Disease (SCD), WEEKLY takes a closer look at the treatments for this autosomal recessive disease, afflicting approximately 100,000 Americans and 25 million globally. Sickle cell anemia is caused by an SNP in the beta globin gene, which codes for hemoglobin—an oxygen-binding protein in red blood … Read More